Trial Profile

A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Etentamig (Primary) ; Lenalidomide (Primary) ; Nirogacestat (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Acronyms Kilimanjaro
Sponsors AbbVie

Most Recent Events

02 Dec 2025 Results presented in the Abbvie media release.
02 Dec 2025 According to a Abbvie media release, data from this trial will be presented at the 2025 American Society of Hematology (ASH) Congress.
13 Jan 2025 Planned number of patients changed from 270 to 320.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com